Recent Quarter Total Invested
$18.42 M
Recent Quarter Institutional Ownership Percentage
5.11%
Total Invested of Last Quarter
$2.46 M
Ownership Percentage of Last Quarter
7.69%
SAB Biotherapeutics, Inc. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| BVF INC/IL | 02/14/2024 | 9.18 M | $6.31 M | 100.00% | 1.75% |
| RTW INVESTMENTS, LP | 02/14/2024 | 9.18 M | $6.31 M | 100.00% | 1.75% |
| SESSA CAPITAL IM, L.P. | 02/14/2024 | 4.58 M | $3.15 M | 100.00% | 0.87% |
| VANGUARD GROUP INC | 03/11/2024 | 996,132 | $684,841 | 1.96% | 0.19% |
| FIRST PREMIER BANK | 01/17/2024 | 807,535 | $555,000 | 0.00% | 0.15% |
| PATHSTONE HOLDINGS, LLC | 02/14/2024 | 506,513 | $348,228 | 100.00% | 0.10% |
| GEODE CAPITAL MANAGEMENT, LLC | 02/13/2024 | 356,364 | $245,072 | 0.00% | 0.07% |
| FIRST MANHATTAN CO. LLC. | 02/13/2024 | 277,777 | $190,971 | 0.00% | 0.05% |
| INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 02/06/2024 | 192,027 | $132,019 | 0.00% | 0.04% |
| KESTRA ADVISORY SERVICES, LLC | 02/14/2024 | 88,000 | $60,500 | 319.05% | 0.02% |
| STATE STREET CORP | 02/14/2024 | 81,241 | $55,853 | 0.00% | 0.02% |
| MARINER, LLC | 02/14/2024 | 69,000 | $47,438 | 0.00% | 0.01% |
| RENAISSANCE TECHNOLOGIES LLC | 02/13/2024 | 63,100 | $43,000 | 8.61% | 0.01% |
| BLACKROCK INC. | 02/13/2024 | 52,643 | $36,192 | 0.00% | 0.01% |
| PEAPACK GLADSTONE FINANCIAL CORP | 02/13/2024 | 52,296 | $36,000 | 0.00% | 0.01% |
| SILVER OAK SECURITIES, INCORPORATED | 02/05/2024 | 51,891 | $35,675 | 0.00% | 0.01% |
| CREATIVE PLANNING | 02/14/2024 | 47,518 | $32,669 | 0.00% | 0.01% |
| ADVISOR GROUP HOLDINGS, INC. | 02/12/2024 | 46,373 | $31,881 | -0.64% | 0.01% |
| NORTHERN TRUST CORP | 02/13/2024 | 44,476 | $30,577 | 0.00% | 0.01% |
| CITADEL ADVISORS LLC | 02/14/2024 | 16,719 | $11,494 | 100.00% | 0.00% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 02/06/2024 | 16,238 | $11,164 | 0.00% | 0.00% |
| TOWER RESEARCH CAPITAL LLC (TRC) | 02/13/2024 | 15,235 | $10,482 | 1.97% | 0.00% |
| NADLER FINANCIAL GROUP, INC. | 02/02/2024 | 13,750 | $9,453 | 0.00% | 0.00% |
| MORGAN STANLEY | 08/16/2024 | 11,506 | $7,910 | -25.31% | 0.00% |
| 1ST SOURCE BANK | 02/08/2024 | 10,000 | $6,875 | 0.00% | 0.00% |
| BAIRD FINANCIAL GROUP, INC. | 02/14/2024 | 10,000 | $6,875 | 0.00% | 0.00% |
| ELGETHUN CAPITAL MANAGEMENT | 02/14/2024 | 5,435 | $6,468 | -45.29% | 0.00% |
| SPECTRUM WEALTH COUNSEL, LLC | 02/14/2024 | 5,030 | $3,459 | 100.00% | 0.00% |
| LM ADVISORS LLC | 02/14/2024 | 3,620 | $2,487 | 100.00% | 0.00% |
| GS INVESTMENTS, INC. | 02/08/2024 | 2,000 | $1,375 | 0.00% | 0.00% |
| JPMORGAN CHASE & CO | 02/12/2024 | 951 | $654 | 2.59% | 0.00% |
| UBS GROUP AG | 02/09/2024 | 500 | $344 | 100.00% | 0.00% |
| FMR LLC | 02/13/2024 | 343 | $236 | 0.00% | 0.00% |
| WELLS FARGO & COMPANY/MN | 02/09/2024 | 294 | $202 | 9.70% | 0.00% |
| NEWEDGE ADVISORS, LLC | 02/13/2024 | 145 | $100 | 0.00% | 0.00% |
| QUBE RESEARCH & TECHNOLOGIES LTD | 02/13/2024 | 69 | $47 | 0.00% | 0.00% |
| BANK OF AMERICA CORP /DE/ | 02/14/2024 | 54 | $38 | 100.00% | 0.00% |
| HARBOUR INVESTMENTS, INC. | 02/16/2024 | 0 | $0 | -100.00% | 0.00% |
| ROYAL BANK OF CANADA | 02/14/2024 | 0 | $0 | -100.00% | 0.00% |
| HIGHTOWER ADVISORS, LLC | 02/12/2024 | 0 | $0 | -100.00% | 0.00% |
| BROOKSTONE CAPITAL MANAGEMENT | 01/11/2024 | 0 | $0 | -100.00% | 0.00% |
| LGL PARTNERS, LLC | 02/05/2024 | 0 | $0 | -100.00% | 0.00% |
| STRATEGIC FINANCIAL CONCEPTS, LLC | 01/18/2024 | 0 | $0 | -100.00% | 0.00% |
SAB Biotherapeutics, Inc.institutional Ownership - Frequently Asked Questions
-
Who are the largest shareholders of SABS shares?
During the previous two years, 4 institutional investors and hedge funds held shares of SAB Biotherapeutics, Inc.. The most heavily invested institutionals were:
PATHSTONE FAMILY OFFICE, LLC: 506,513
Veritable, L.P.: 506,513
American Portfolios Advisors: 17,466
Spectrum Management Group, LLC: 5,030
-
What percentage of SAB Biotherapeutics, Inc. stock is owned by institutional investors?
5.11% of SAB Biotherapeutics, Inc. stock is owned by institutional investors.
-
How much institutional buying is happening at SABS ?
Institutional investors have bought a total of 1.04 M shares in the last 24 months. This purchase volume represents approximately $2.71 M in transactions.